Viking Therapeutics' Price Target of $93.39 Implies 175% Upside Potential
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: NASDAQ.COM
- Slow Clinical Progress: Viking Therapeutics has made little clinical progress over the past year, leading to poor stock performance, and its major data releases were not well received by the market, resulting in a sell-off that affected investor confidence.
- Price Target Analysis: Analysts have set an average price target of $93.39 for Viking, implying a 175% upside from current levels, indicating optimistic market expectations for its future potential despite inherent risks.
- VK2735 Research Progress: Viking's VK2735 is undergoing a 78-week phase 3 study, with results expected in 2027; however, if the results are strong, they could significantly boost the stock price, showcasing its competitiveness in the weight loss market.
- Pipeline Diversification: Viking is also conducting a maintenance study for VK2735, testing various administration methods, demonstrating the company's forward-thinking approach in weight loss drug development, although short-term stock price fluctuations may be limited, the long-term potential is worth noting.
Analyst Views on VKTX
Wall Street analysts forecast VKTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VKTX is 97.00 USD with a low forecast of 70.00 USD and a high forecast of 125.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Analyst Rating
12 Buy
0 Hold
0 Sell
Strong Buy
Current: 33.520
Low
70.00
Averages
97.00
High
125.00
Current: 33.520
Low
70.00
Averages
97.00
High
125.00
About VKTX
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on the development of therapies for the treatment of metabolic and endocrine disorders. Its clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptors for the potential treatment of various metabolic disorders. It is evaluating an oral formulation of VK2735 in a Phase II trial. It is also developing VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders. Its newest program is evaluating a series of internally developed dual amylin and calcitonin receptor agonists for the treatment of obesity and other metabolic disorders. In the rare disease space, it is developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
